Last reviewed · How we verify
NCT05186064: GLOW
Glioblastoma Targeted Treatment Option Maximization by WGS
NA trial testing whole genome sequencing in Glioblastoma in 160 participants. Currently enrolling.
1 July 2024
Quick facts
| Lead sponsor | UMC Utrecht |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 160 |
| Start date | 25 July 2022 |
| Primary completion | 1 July 2024 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- whole genome sequencing
Conditions studied
- Glioblastoma — all drugs for Glioblastoma →
Sponsor
UMC Utrecht — full company profile →
Who can join
18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Study protocol of the GLOW study: maximising treatment options for recurrent glioblastoma patients by whole genome sequencing-based diagnostics-a prospective multicenter cohort study.
van Opijnen MP, Broekman MLD, de Vos FYF, Cuppen E, et al · · 2022 · cited 6× · PMID 36333718 · DOI 10.1186/s12920-022-01343-4 -
Whole genome sequencing-based analysis of genetic predisposition to adult glioblastoma.
van Opijnen MP, van Valkengoed DR, de Ligt J, de Vos FYF, et al · · 2025 · cited 1× · PMID 41168197 · DOI 10.1038/s41525-025-00526-z
Verify or expand the search:
- PubMed search for NCT05186064
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of whole genome sequencing
Trials testing the same drug.
- NCT06546137 — National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Un · recruiting
- NCT05793515 — Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models · completed
Other recruiting trials for Glioblastoma
Currently open trials in the same condition.
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other UMC Utrecht trials
Trials by the same sponsor.
- NCT07512336 — A Randomized Intra-Patient Controlled Trial of MagnetOs™ Putty vs Autograft in Instrumented Posterolateral Spinal Fusion · NA · not yet recruiting
- NCT07485985 — Coronary Sinus Reducer Therapy for Persisting Angina · NA · not yet recruiting
- NCT07449052 — Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease · NA · not yet recruiting
- NCT05375708 — Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Me · Phase 2 · suspended
- NCT06898541 — Coronary Sinus Reducer in Coronary Microvascular Disease · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05186064 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by UMC Utrecht
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186064.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing